Kyverna Therapeutics, Inc. (KYTX) stock
Close on Nov 13, 2026Market cap $312.31MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $312.31M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 2.35
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$157.79M
- EPS, diluted
- -$2.77
- Free cash flow
- -$153.72M
- Book value per share
- $2.15
- Diluted shares
- 62M
Trading
- Next earnings
- Mar 25, 2027 (estimated, during market hours)
- Previous close
- $5.03
- Open
- $5.54
- Day's range
- $4.82 – $5.54
- Volume
- 834,496
- Average volume (20 days)
- 833,215
- Index membership
- Russell 2000 (since Jun 2026)
- Beta (5 years)
- 1.76
- 52-week range
- $4.50 – $13.67
- RSI (14 days)
- 39.0
- Volatility (1 year)
- 87.0%
- Relative volume
- 0.94×
- WACC
- 13.5%
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2024, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | KYTX | S&P 500 | Difference | KYTX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -12.5% | -3.0% | −9.4 pts | ||
| 3 months | -37.5% | -2.8% | −34.7 pts | ||
| Year to date | -46.3% | +11.5% | −57.8 pts | ||
| 1 year | -22.1% | +13.5% | −35.5 pts |
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Kyverna Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Update
- News
- Results
About Kyverna Therapeutics
Biological Products, (No Diagnostic Substances)
Kyverna Therapeutics, Inc. is a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. The company concentrates primarily on its neuroimmunology CAR T franchise to achieve immune reset and treatment-free remission. Its lead product candidate is mivocabtagene autoleucel (miv-cel, or KYV-101), an autologous, fully human CD19-targeting CAR T-cell therapy being developed for serious conditions including stiff person syndrome and generalized myasthenia gravis. Additionally, the company explores pipeline expansion into other autoimmune indications such as progressive multiple sclerosis, rheumatoid arthritis, lupus nephritis, and systemic sclerosis, as well as novel manufacturing platforms such as KYV-102.
Company profile, executives and historyKyverna Therapeutics stock: common questions
What is Kyverna Therapeutics's stock price?
KYTX closed at $5.05 on Nov 13, 2026, up 0.40% on the day. Over the past 52 weeks it traded between $4.50 and $13.67.
What is Kyverna Therapeutics's market cap?
Kyverna Therapeutics was worth $312.31M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is KYTX's P/E ratio?
Kyverna Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$2.77), so it has no meaningful P/E ratio.
Does Kyverna Therapeutics pay a dividend?
No. Kyverna Therapeutics has not paid a cash dividend over the last twelve months.
When does Kyverna Therapeutics report earnings next?
Kyverna Therapeutics is expected to report Q4 FY2026 results on Mar 25, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has KYTX stock performed over the past year?
Including dividends, KYTX returned -22.1% over the past year, against +13.5% for the S&P 500.
How many KYTX shares are sold short?
9M shares were sold short at the latest FINRA report, 16.25% of the float, or 11.6 days of average trading volume.
Who are Kyverna Therapeutics's competitors?
Companies most similar to Kyverna Therapeutics by business, industry and size include CABA, ARTV, INAB, CGEM, IMVT.
See a number that looks wrong?